Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8323737 | 0.98 | PKM (0.71) | PKMHTTPOLBSMN1; SMN2DDAH1 | |
| SCHEMBL1884521 | 0.90 | POLB (0.72) | PKMHTTPOLBSMN1; SMN2DDAH1 | |
| SCHEMBL7273283 | 0.89 | POLB (0.75) | PKMHTTPOLBSMN1; SMN2DDAH1 | |
| SCHEMBL7265452 | 0.87 | POLB (0.73) | PKMHTTPOLBSMN1; SMN2DDAH1 | |
| SCHEMBL7267160 | 0.87 | POLB (0.73) | PKMHTTPOLBSMN1; SMN2DDAH1 | |
| SCHEMBL7275409 | 0.87 | POLB (0.73) | PKMHTTPOLBSMN1; SMN2DDAH1 | |
| SCHEMBL21486245 | 0.83 | SMN1; SMN2 (0.63) | PKMHTTPOLBSMN1; SMN2DDAH1 | |
| SCHEMBL230157 | 0.83 | POLB (0.84) | PKMPOLBDDAH1NPC1RAB9A | |
| SCHEMBL13439413 | 0.83 | POLB (0.66) | PKMHTTPOLBSMN1; SMN2DDAH1 | |
| SCHEMBL336412 | 0.82 | PKM (0.96) | PKMPOLBSMN1; SMN2DDAH1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150618-A2 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2021191202-A1 | PROCESS FOR THE PRODUCTION OF FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| US-9422308-B2 | Derivatives of docosahexaenoylethanolamide and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-01-29 | — | — | US | disclosed |
| EP-2152670-B1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2152670-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132679-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-06 | — | — | WO | disclosed |
| EP-0869787-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0226016-A1 | Process for inhibiting hydrogen-induced corrosion of metallic materials | BAYER AG (DE) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | GAP43, DGAT2, DCX | PKM 4289/4885HTT 1788/4885POLB 1719/4885 |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | CACNA1E, CACNA1B, CACNA1A | PKM 4209/4885HTT 2887/4885POLB 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.